Article
Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.
British journal of haematology - 1 Feb 2009
Papadaki Christina, Dufour Annika, Seibl Marlene, Schneider Stephanie, Bohlander Stefan K, Zellmeier Evelyn, Mellert Gudrun, Hiddemann Wolfgang, Spiekermann Karsten
Abstract excerpt
Nucleophosmin (NPM1) mutations in exon 12 represent the most frequent molecular aberrations in adult patients with acute myeloid leukaemia (AML). Molecular detection of NPM1 mutation A could be a useful marker for routine monitoring of minimal residual disease (MRD). We established a calibrator-normalized relative quantification real-time polymerase chain reaction (PCR) assay for NPM1 mutation A. ABL1 was used as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.